2020
Added Diagnostic Utility of Clinical Metagenomics for the Diagnosis of Pneumonia in Immunocompromised Adults
Azar MM, Schlaberg R, Malinis MF, Bermejo S, Schwarz T, Xie H, Dela Cruz CS. Added Diagnostic Utility of Clinical Metagenomics for the Diagnosis of Pneumonia in Immunocompromised Adults. CHEST Journal 2020, 159: 1356-1371. PMID: 33217418, DOI: 10.1016/j.chest.2020.11.008.Peer-Reviewed Original ResearchConceptsFinal clinical diagnosisDiagnostic yieldFungal pneumoniaImmunocompromised adultsMicrobiologic diagnosisAntimicrobial stewardshipMicrobiologic testingClinical diagnosisClinical metagenomicsCommunity-acquired pneumoniaStandard of careDiagnosis of pneumoniaAdult patientsRadiologic findingsBacterial pneumoniaBAL fluidProspective studyViral pneumoniaBacterial causePneumoniaDiagnostic utilityStudy designDiagnosisAdultsHypothetical impact
2019
Use of Routine Complete Blood Count Results to Rule Out Anaplasmosis Without the Need for Specific Diagnostic Testing
Turbett SE, Anahtar MN, Pattanayak V, Azar MM, Coffey KC, Eng G, Rudolf JW, Lewandrowski KB, Baron J, Rosenberg ES, Branda JA. Use of Routine Complete Blood Count Results to Rule Out Anaplasmosis Without the Need for Specific Diagnostic Testing. Clinical Infectious Diseases 2019, 70: 1215-1221. PMID: 31044232, PMCID: PMC7346887, DOI: 10.1093/cid/ciz346.Peer-Reviewed Original ResearchMeSH KeywordsAnaplasma phagocytophilumAnaplasmosisAnimalsBlood Cell CountDiagnostic Techniques and ProceduresHumansProspective StudiesRetrospective StudiesConceptsComplete blood countWhite blood cellsPolymerase chain reactionBlood countLiver function test resultsRoutine complete blood countMedical record reviewSpecific diagnostic testingFunction test resultsRoutine laboratory testsPositive PCR resultsTrue positive casesTrue negative casesLaboratory abnormalitiesRecord reviewRetrospective reviewPlatelet countClinical criteriaTime of testingProspective phasePCR testingPLT countStewardship programsClinical situationsDiagnostic testing
2018
Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community
Springer SA, Di Paola A, Azar M, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 43-53. PMID: 29373393, PMCID: PMC5889326, DOI: 10.1097/qai.0000000000001634.Peer-Reviewed Original ResearchMeSH KeywordsAdultCriminal LawDelayed-Action PreparationsDouble-Blind MethodFemaleFollow-Up StudiesHIV InfectionsHIV-1HumansInjections, IntramuscularMaleMiddle AgedMultivariate AnalysisNaltrexoneNarcotic AntagonistsOpioid-Related DisordersPrisonersProspective StudiesResearch DesignRNA, ViralTime FactorsTreatment OutcomeViral LoadConceptsOpioid use disorderViral suppressionXR-NTXPlacebo groupPrimary outcomeUse disordersXR-NTX groupPlacebo-controlled trialExtended-release naltrexoneStatistical significant differenceRelease naltrexoneMonthly injectionsEligible participantsTreatment groupsJail detaineesHIVMonthsBaselinePlaceboSignificant differencesNaltrexoneJail inmatesDisordersVS levelsOutcomes